



Company Contact - Jim Dorsey
BioClinica, Inc.
267-757-3040

Trade Media – Rachel Summers
Diccicco Battista Communications
484-342-3600

Investor Contact - Michael Porter
Financial Media - Bill Gordon
Porter, LeVay & Rose, Inc.
212-564-4700

FOR IMMEDIATE RELEASE

HARRISON CLINICAL RESEARCH SELECTS BIOCLINICA ONPOINT CTMS

- Leading European CRO Chooses 'Flexible and Affordable' Clinical Trial Management (CTMS) Technology -

NEWTOWN, PA, January 17, 2012 – BioClinica[®], Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, announced today a new agreement with Harrison Clinical Research (HCR), an international full-service contract research organization. After notification that support for its previous CTMS solution would be discontinued, Harrison selected BioClinica OnPoint CTMS to replace that system. HCR decided that OnPoint is the best-in-class solution to provide services to its world-wide client base. Harrison currently supports approximately 80 clinical trials for its clients annually.

“After an extensive product search, we were impressed with BioClinica’s technology and the operational efficiencies that it affords,” said Monika Huber, Group Compliance Manager and Project Director of Harrison Clinical Research. “A robust CTMS system is critical for us to support trial management and optimal communication with our clients. Both our IT and clinical teams liked BioClinica’s team and the technology, and in particular, how flexible and affordable it was compared to other solutions. BioClinica’s product roadmap for OnPoint convinced us that it is the right partner for the long haul.”

Harrison’s in-depth selection process included a pilot project that offered users hands-on validation of OnPoint’s capabilities and ease-of-use. “Harrison was already a Microsoft® SharePoint® customer,” said Ms. Huber, “and when we saw the offline capabilities – through OnPoint to Outlook and Microsoft Office – we were even more impressed.” BioClinica OnPoint leverages native connectivity through SharePoint to extend workflow management to Microsoft Office applications which allow end users to do much of their work using their familiar desktop applications.

“BioClinica is delighted to be chosen by Harrison Clinical Research for its world-wide clinical trial management needs after such a thorough selection process,” said Peter Benton, President of eClinical Solutions for BioClinica. “Since launching the latest release of the product eight months ago, we have seen tremendous interest in OnPoint’s ability to support global research combined with the flexibility sponsors need to create more efficient eClinical environments.”

BioClinica OnPoint CTMS capabilities include: clinical site, personnel, patient and clinical supplies administration; scheduling, tracking and performance monitoring; site payments, study document management; and more. OnPoint CTMS is supported by Microsoft SharePoint and BioClinica technologies to provide superior team collaboration, connectivity and efficiency for multi-site implementations.

Follow BioClinica on the Trial Blazers blog at <http://info.bioclinica.com/blog>, and on twitter at <http://twitter.com/bioclinica>.

-more-

About the Harrison Clinical Research Group

Harrison Clinical Research (HCR) is an international contract research organization offering full service clinical research capabilities to the pharmaceutical industry. With Phase I (clinical pharmacology unit in Munich, Germany) to Phase IV capabilities, HCR focuses on providing the services our clients require for the successful clinical development and registration of new pharmaceutical, biological and nutraceuticals products as well as medical devices by delivering the highest quality data, achieving promised enrollment and meeting project timelines.

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

#####